Literature DB >> 21340521

Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now : Commentary to: 10.1007/s00415-010-5844-5 "One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients" by S. Malucchi et al.

Til Menge1, Hans-Peter Hartung, Bernd C Kieseier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21340521     DOI： 10.1007/s00415-011-5941-0

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  38 in total

1.  Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

Authors:  Hillel Panitch; Aaron Miller; Donald Paty; Brian Weinshenker
Journal:  Neurology       Date:  2004-11-23       Impact factor: 9.910

Review 2.  Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis.

Authors:  Bernhard Hemmer; Olaf Stüve; Bernd Kieseier; Huub Schellekens; Hans-Peter Hartung
Journal:  Lancet Neurol       Date:  2005-07       Impact factor: 44.182

3.  Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.

Authors:  L F van der Voort; A Kok; A Visser; C B M Oudejans; M Caldano; F Gilli; A Bertolotto; C H Polman; J Killestein
Journal:  Mult Scler       Date:  2008-09-19       Impact factor: 6.312

4.  Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.

Authors:  Chris H Polman; Antonio Bertolotto; Florian Deisenhammer; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Joep Killestein; Henry F McFarland; Joel Oger; Andrew R Pachner; John Petkau; Anthony T Reder; Stephen C Reingold; Huub Schellekens; Per Soelberg Sørensen
Journal:  Lancet Neurol       Date:  2010-07       Impact factor: 44.182

5.  Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta.

Authors:  Ajith Sominanda; Malin Lundkvist; Anna Fogdell-Hahn; Bernhard Hemmer; Hans-Peter Hartung; Jan Hillert; Til Menge; Bernd C Kieseier
Journal:  Arch Neurol       Date:  2010-09

6.  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

7.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

8.  Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.

Authors:  G Giovannoni; O Barbarash; F Casset-Semanaz; J King; L Metz; G Pardo; J Simsarian; P S Sørensen; B Stubinski
Journal:  Mult Scler       Date:  2008-08-28       Impact factor: 6.312

9.  Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b.

Authors:  C Polman; L Kappos; R White; F Dahlke; K Beckmann; C Pozzilli; A Thompson; J Petkau; D Miller
Journal:  Neurology       Date:  2003-01-14       Impact factor: 9.910

10.  Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis.

Authors:  L Jacobs; A M Salazar; R Herndon; P A Reese; A Freeman; R Josefowicz; A Cuetter; F Husain; W A Smith; R Ekes
Journal:  Lancet       Date:  1986 Dec 20-27       Impact factor: 79.321
View more
  3 in total

1.  Progress in multiple sclerosis research in the last year.

Authors:  Daniela Galimberti; Elio Scarpini
Journal:  J Neurol       Date:  2012-06-22       Impact factor: 4.849

2.  [Alemtuzumab: a further option for treatment of multiple sclerosis].

Authors:  T Menge; B C Kieseier; C Warnke; O Aktas; H-P Hartung
Journal:  Nervenarzt       Date:  2012-04       Impact factor: 1.214

3.  The cross-reactivity of binding antibodies with different interferon beta formulations used as disease-modifying drugs in multiple sclerosis patients.

Authors:  Agnieszka Wencel-Warot; Slawomir Michalak; Marcin Warot; Alicja Kalinowska-Lyszczarz; Radoslaw Kazmierski
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.